Table 2.

Bleeding events

Patient sex	Age, y	Critically ill	Type(s) of bleeding	Platelet count at bleed(s), ×109/L	Anticoagulation at bleed(s)	WHO grade(s)	Comments
Male	67	Yes	GI	47	Therapeutic (UFH)	2	On anticoagulation for pulmonary embolus and clotting of CVVH circuit at time of bleed
Male	59	No	Hemoptysis	134	None	1	Recurrent
Male	62	Yes	GI	242	Prophylactic (UFH)	3
Male	37	No	Hemoptysis	426	Prophylactic (enoxaparin)	2
Male	68	Yes	Oral mucosa bleeding	227	Prophylactic (enoxaparin)	2	Recurrent
Male	56	No	Epistaxis	208	Prophylactic (enoxaparin)	2	Recurrent
Male	49	Yes	Epistaxis; bleeding from multiple cannulation sites	115; 184	Prophylactic (enoxaparin) for both events	3; 1	Epistaxis recurrent and required otolaryngology consult and prolonged packing; DIC
Male	59	Yes	Bleeding from multiple cannulation sites; intracranial hemorrhage	155; 257	Therapeutic (UFH) for both events	1; 4	Fatal intracranial hemorrhage; DIC
Female	65	Yes	Internal bleeding	177	Prophylactic (UFH)	3	Recurrent; strong clinical suspicion of internal bleeding due to rapidly declining hemoglobin (>2 g/dL drop each time requiring transfusion) with no other cause (unable to scan)
Male	69	Yes	Oropharyngeal bleeding from tongue mass	414	Prophylactic (UFH)	2	Recurrent; required consult from otolaryngology and prolonged oral packing. Tongue mass was a suspected, but not a known, cancer.
Male	34	No	Hemoptysis	142	Therapeutic (UFH)	1
Female	44	Yes	Pulmonary hemorrhage	47	Therapeutic (UFH)	3	Anticoagulated with impella in place; DIC
Male	79	Yes	GI	297	Therapeutic (UFH)	3
Male	67	No	Spontaneous right kidney hematoma	157	Prophylactic (enoxaparin)	2
Male	59	Yes	GI	1	None	3	Developed COVID-19–associated immune thrombocytopenia 3 d prior to bleed
Male	83	No	GI	46	Warfarin	2	INR: 6.5 at time of bleed
Male	84	No	GI	66	Warfarin	2	INR: 1.5 at time of bleed
Male	70	No	GI	262	Clopidogrel	3
Male	65	Yes	GI	59	Prophylactic (enoxaparin)	3

GI, gastrointestinal.